Practice of Rapid Selection and Evaluation of New Oral Small-Molecule Anti-COVID-19 Drugs
OBJECTIVE:To perform rapid selection and evaluation of new oral small-molecule anti-COVID-19 drugs based on Rapid Guidelines for Drug Evaluation and Selection in Chinese Medical Institutions(Second Edition)(hereinafter referred to as"the guidelines"),so as to provide reference for the rational introduction of drugs by medical institutions.METHODS:By referring to drug instructions,disease diagnosis and treatment guidelines,and through retrieving literature from databases such as CNKI,Wanfang Data and PubMed,a percentile evaluation system based on guidelines was developed to evaluate the hygiene technology of Nematovir/Litonavir tablets,Monovir capsules,and Azvudine tablets from five aspects:pharmaceutical characteristics,efficacy,safety,economy,and other attributes.According to the score results,the introduction level of various drugs was recommended.RESULTS:After quantitative evaluation,the final scores of Azvudine tablets,Nematoveir/Litonavir tablets,and Monovir capsules were respectively 75.00,71.78 and 73.36 points.All three were first-line drugs for early treatment of mild and medium-COVID-19 patients.Azulfidine tablets were more widely available and cheaper,but had a slightly higher incidence of adverse drug reactions such as diarrhea and dizziness.Nematrevir/Ritonavir tablets and Monovir capsules were restricted to adults with risk factors for developing a heavy form of the disease,and Nematrevir/Ritonavir tablets were more efficacious than Monovir capsules,but had more adverse drug interactions and were expensive.Monoravir capsules did not require dose adjustment when used in patients with abnormal hepatic or renal function,with no adverse drug interactions,and had the lowest incidence of mild to moderate adverse drug reactions.The total score of the three drugs was＞70 points,which belonged to the category of strong recommendation.Medical institutions could choose 1 to 2 types of introduction according to the characteristics of the medication population.CONCLUSIONS:This health technology assessment can provide practical experience for medical institutions to carry out drug selection and evaluation,as well as evidence-based evidence for rational clinical use of anti-COVID-19 drugs.
Health technology assessmentDrug selectionNematavir/Ritonavir tabletsMonoravir capsulesAzifudine tablets
万方数据
维普
